5.56
price up icon3.93%   0.21
after-market After Hours: 5.56
loading
Nevro Corp stock is traded at $5.56, with a volume of 869.28K. It is up +3.93% in the last 24 hours and up +11.87% over the past month.
See More
Previous Close:
$5.35
Open:
$5.32
24h Volume:
869.28K
Relative Volume:
1.45
Market Cap:
$218.11M
Revenue:
$425.17M
Net Income/Loss:
$-92.21M
P/E Ratio:
556.00
EPS:
0.01
Net Cash Flow:
$-67.42M
1W Performance:
+5.90%
1M Performance:
+11.87%
6M Performance:
-50.75%
1Y Performance:
-65.40%
1-Day Range:
Value
$5.22
$5.66
1-Week Range:
Value
$5.10
$5.71
52-Week Range:
Value
$4.382
$22.64

Nevro Corp Stock (NVRO) Company Profile

Name
Name
Nevro Corp
Name
Phone
650-251-0005
Name
Address
1800 BRIDGE PARKWAY, REDWOOD CITY, CA
Name
Employee
0
Name
Twitter
@Nevro_HF10
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
NVRO's Discussions on Twitter

Nevro Corp Stock (NVRO) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-12-24 Downgrade RBC Capital Mkts Outperform → Sector Perform
Dec-21-23 Downgrade Canaccord Genuity Buy → Hold
Jul-19-23 Initiated Robert W. Baird Neutral
May-31-23 Initiated RBC Capital Mkts Outperform
May-15-23 Upgrade Oppenheimer Perform → Outperform
Apr-14-23 Initiated Mizuho Neutral
Jan-17-23 Downgrade Citigroup Buy → Neutral
Jan-06-23 Downgrade Piper Sandler Neutral → Underweight
Dec-20-22 Upgrade Canaccord Genuity Hold → Buy
Dec-12-22 Downgrade Wells Fargo Overweight → Equal Weight
Oct-12-22 Initiated Jefferies Underperform
May-05-22 Upgrade Citigroup Neutral → Buy
Apr-13-22 Resumed Truist Hold
Apr-06-22 Initiated Wolfe Research Underperform
Mar-02-22 Resumed BofA Securities Underperform
Jan-07-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-06-21 Upgrade Wells Fargo Equal Weight → Overweight
Nov-09-21 Downgrade Truist Buy → Hold
Aug-05-21 Downgrade Canaccord Genuity Buy → Hold
Aug-05-21 Downgrade Citigroup Buy → Neutral
Aug-05-21 Downgrade Piper Sandler Overweight → Neutral
Aug-05-21 Downgrade Wells Fargo Overweight → Equal Weight
Aug-05-21 Downgrade William Blair Outperform → Mkt Perform
Jul-09-21 Downgrade Redburn Buy → Neutral
Jul-06-21 Downgrade Robert W. Baird Outperform → Neutral
Feb-02-21 Initiated Piper Sandler Overweight
Oct-23-20 Initiated Guggenheim Buy
Sep-02-20 Initiated Robert W. Baird Outperform
Jun-08-20 Upgrade UBS Sell → Neutral
Mar-05-20 Initiated Citigroup Buy
Feb-26-20 Upgrade Canaccord Genuity Hold → Buy
Jan-08-20 Initiated SunTrust Buy
Jan-06-20 Downgrade Oppenheimer Outperform → Perform
Nov-07-19 Upgrade Oppenheimer Perform → Outperform
Oct-22-19 Initiated Oppenheimer Perform
Mar-20-19 Upgrade BofA/Merrill Neutral → Buy
Mar-20-19 Upgrade Wells Fargo Market Perform → Outperform
Nov-28-18 Initiated UBS Sell
Nov-07-18 Downgrade BofA/Merrill Buy → Neutral
Nov-06-18 Downgrade JP Morgan Overweight → Neutral
Nov-06-18 Downgrade Morgan Stanley Equal-Weight → Underweight
Oct-19-18 Downgrade Goldman Neutral → Sell
Jul-02-18 Downgrade Morgan Stanley Overweight → Equal-Weight
May-08-18 Reiterated Canaccord Genuity Buy
May-08-18 Downgrade Northland Capital Outperform → Market Perform
May-08-18 Downgrade Wells Fargo Outperform → Market Perform
View All

Nevro Corp Stock (NVRO) Latest News

pulisher
Nov 04, 2024

Nevro (NVRO) to Release Earnings on Monday - MarketBeat

Nov 04, 2024
pulisher
Nov 03, 2024

Nevro (FRA:1N7) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com

Nov 03, 2024
pulisher
Nov 01, 2024

Nevro (NYSE:NVRO) Upgraded to Hold at StockNews.com - MarketBeat

Nov 01, 2024
pulisher
Oct 30, 2024

Assenagon Asset Management S.A. Increases Position in Nevro Corp. (NYSE:NVRO) - MarketBeat

Oct 30, 2024
pulisher
Oct 29, 2024

New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy - PR Newswire

Oct 29, 2024
pulisher
Oct 29, 2024

Nevro Corp. (NYSE:NVRO) Receives Average Rating of "Reduce" from Analysts - MarketBeat

Oct 29, 2024
pulisher
Oct 28, 2024

President & CEO Thornal Kevin R covered exercise/tax liability with 6,063 shares, decreasing direct ownership by 2% to 249,847 units (SEC Form 4) - Quantisnow

Oct 28, 2024
pulisher
Oct 24, 2024

Chronic Pain Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | AstraZeneca, Regenacy Pharma, Nevro Corp., Erchonia Corporation - The Globe and Mail

Oct 24, 2024
pulisher
Oct 24, 2024

StockNews.com Upgrades Nevro (NYSE:NVRO) to Hold - MarketBeat

Oct 24, 2024
pulisher
Oct 18, 2024

Trading (NVRO) With Integrated Risk Controls - Stock Traders Daily

Oct 18, 2024
pulisher
Oct 17, 2024

Nevro announces new inducement grants - Medical Buyer

Oct 17, 2024
pulisher
Oct 16, 2024

StockNews.com Lowers Nevro (NYSE:NVRO) to Sell - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Nevro shares target cut by Baird, retains neutral stance - Investing.com Australia

Oct 16, 2024
pulisher
Oct 16, 2024

Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - Marketscreener.com

Oct 16, 2024
pulisher
Oct 15, 2024

Nevro Corp (NVRO) PT Lowered to $5 at Baird - StreetInsider.com

Oct 15, 2024
pulisher
Oct 12, 2024

Nevro Corp. (NYSE:NVRO) Shares Sold by Dimensional Fund Advisors LP - MarketBeat

Oct 12, 2024
pulisher
Oct 10, 2024

Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024 - BioSpace

Oct 10, 2024
pulisher
Oct 10, 2024

Millennium Management LLC Increases Holdings in Nevro Corp. (NYSE:NVRO) - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

Here's Why You Should Retain Nevro (NVRO) Stock for Now - MSN

Oct 09, 2024
pulisher
Oct 08, 2024

SVP, Corp Dev and CLO Rashid Kashif covered exercise/tax liability with 479 shares, decreasing direct ownership by 0.30% to 161,352 units (SEC Form 4) - Quantisnow

Oct 08, 2024
pulisher
Oct 06, 2024

Nevro obtains FDA approval for AI-based spinal cord stimulation system - MSN

Oct 06, 2024
pulisher
Oct 04, 2024

Nevro Corp. (NYSE:NVRO) Shares Purchased by Point72 Asset Management L.P. - MarketBeat

Oct 04, 2024
pulisher
Oct 04, 2024

Nevro Corp. (NYSE:NVRO) Receives $10.55 Consensus Price Target from Brokerages - MarketBeat

Oct 04, 2024
pulisher
Oct 03, 2024

Nevro Corp. (NYSE:NVRO) Shares Sold by Cubist Systematic Strategies LLC - MarketBeat

Oct 03, 2024
pulisher
Oct 01, 2024

Breaking Down Nevro: 10 Analysts Share Their Views - Benzinga

Oct 01, 2024
pulisher
Oct 01, 2024

Nevro (NYSE:NVRO) PT Lowered to $6.00 at Citigroup - MarketBeat

Oct 01, 2024
pulisher
Sep 30, 2024

Nevro Corp.'s SWOT analysis: stock faces headwinds amid SCS market challenges - Investing.com India

Sep 30, 2024
pulisher
Sep 30, 2024

Nevro Corp.'s SWOT analysis: stock faces headwinds amid SCS market challenges By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 26, 2024

Where are the Opportunities in (NVRO) - Stock Traders Daily

Sep 26, 2024
pulisher
Sep 26, 2024

Here's Why you Should Retain Nevro Stock in Your Portfolio Now - Yahoo Finance

Sep 26, 2024
pulisher
Sep 26, 2024

Nevro Corp. (NYSE:NVRO) Shares Sold by Fred Alger Management LLC - MarketBeat

Sep 26, 2024
pulisher
Sep 25, 2024

NVRO Stock May Gain on the FDA Approval of Its HFX AdaptivAI Platform - Yahoo Finance

Sep 25, 2024
pulisher
Sep 24, 2024

Nevro wins FDA nod for AI-driven spinal cord stimulation tech - Mass Device

Sep 24, 2024
pulisher
Sep 24, 2024

Nevro Announces the Launch of HFX AdaptivAI™, the Only AI-Driven Technology in Spinal Cord Stimulation - PR Newswire

Sep 24, 2024
pulisher
Sep 17, 2024

Global Electrotherapy System Research Report 2024: A $1.65 Billion Market by 2030 - GlobeNewswire Inc.

Sep 17, 2024
pulisher
Sep 15, 2024

Nevro Corp. (NYSE:NVRO) Stake Raised by Acadian Asset Management LLC - MarketBeat

Sep 15, 2024
pulisher
Sep 12, 2024

Vanguard Group Inc's Strategic Reduction in Nevro Corp Holdings - Yahoo Finance

Sep 12, 2024
pulisher
Sep 09, 2024

Nevro Corp. (NYSE:NVRO) Given Consensus Recommendation of "Reduce" by Analysts - MarketBeat

Sep 09, 2024
pulisher
Sep 06, 2024

Nevro (NYSE:NVRO) Share Price Passes Below 50-Day Moving Average of $7.62 - MarketBeat

Sep 06, 2024
pulisher
Sep 06, 2024

Microelectronic Medical Implants Market Report 2024-2029, with Profiles of Leading Players, including Abbott, Biotronik, Cochlear, LivaNova, Medtronic, Neuropace and Nevro - Yahoo Finance UK

Sep 06, 2024
pulisher
Aug 31, 2024

(NVRO) Trading Report - Stock Traders Daily

Aug 31, 2024
pulisher
Aug 30, 2024

SVP, Corp Dev and CLO Rashid Kashif covered exercise/tax liability with 817 shares, decreasing direct ownership by 0.50% to 163,590 units (SEC Form 4) - Quantisnow

Aug 30, 2024
pulisher
Aug 28, 2024

Nevro to Present at Wells Fargo 2024 Healthcare Conference - The Malaysian Reserve

Aug 28, 2024
pulisher
Aug 21, 2024

Nevro (NYSE:NVRO) Lowered to "Sell" at StockNews.com - MarketBeat

Aug 21, 2024
pulisher
Aug 19, 2024

Assenagon Asset Management S.A. Has $6.13 Million Position in Nevro Corp. (NYSE:NVRO) - MarketBeat

Aug 19, 2024
pulisher
Aug 19, 2024

Nathan B Pliam Net Worth (2024) - GuruFocus.com

Aug 19, 2024
pulisher
Aug 15, 2024

Nevro Corp. (NYSE:NVRO) Given Average Recommendation of "Reduce" by Analysts - MarketBeat

Aug 15, 2024
pulisher
Aug 15, 2024

Nevro Corp. (NYSE:NVRO) Given Average Rating of “Reduce” by Brokerages - Defense World

Aug 15, 2024

Nevro Corp Stock (NVRO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
medical_devices ZBH
$108.92
price up icon 0.47%
medical_devices STE
$227.44
price up icon 0.72%
medical_devices PHG
$27.08
price up icon 0.00%
$69.00
price down icon 1.00%
$88.17
price up icon 1.36%
medical_devices EW
$66.69
price up icon 0.33%
Cap:     |  Volume (24h):